Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
VievePharm is renowned for its phytogenic formulations across livestock, equine, and pet care markets
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
Subscribe To Our Newsletter & Stay Updated